-
Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma
18 Dec 2024 16:06 GMT
… (SHARP) trials, sorafenib significantly improved the prognosis … in patients taking sorafenib primarily included gastrointestinal, … between ferroptosis and sorafenib resistance, suggesting ferroptosis … renal, liver, and lung cancers, and has been implicated …
-
Circ_0001944 Targets the miR-1292-5p/FBLN2 Axis to Facilitate Sorafenib Resistance in Hepatocellular Carcinoma by Impeding Ferroptosis
26 Nov 2024 06:14 GMT
… obtained after sorafenib usage in sorafenib-resistant patients … -shRNA/sorafenib group versus sorafenib-treated group, … shRNA/sorafenib group.
.
Discussion
Sorafenib represents a … non-small cell lung cancer progression via destabilizing IGF2BPs …
-
Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade
06 Sep 2024 05:53 GMT
… and mortality rates of lung cancer have been steadily increasing … with various malignancies, including lung cancer.35 Finally, we combined … carcinoma previously treated with sorafenib: the checkmate 040 … with non-small-cell lung cancer (CheckMate 9LA): an …
-
Mesoporous Graphene Oxide Nanocomposite Effective for Combined Chemo/Photo Therapy Against Non-Small Cell Lung Cancer
24 Jul 2024 08:34 GMT
… Cancer Epidemiology Report (2024), lung cancer ranks as the most … to load chemotherapy drugs Sorafenib and FeS2 nanoparticles for … , China) and human lung cancer A549 cells were obtained from … T790M positive non-small cell lung cancer: OSCILLATE. Nat Commun. …
-
Research Progress on the Anti-Liver Cancer Mechanism and Toxicity of Rhubarb Anthraquinone
17 Dec 2024 15:04 GMT
… systemic antitumor therapy include sorafenib, tislelizumab monoclonal antibody, … potential therapeutic drugs for lung cancer, colon cancer, liver … non-small-cell lung cancer through inhibiting the … the Cytotoxicity of Sorafenib in Hepatocellular Carcinoma. …
-
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
03 Jun 2024 12:19 GMT
… to biomarkers.
About Lung Cancer
Lung cancer is the leading cause … positive) non-small cell lung cancer (NSCLC).
OPDIVO® (nivolumab … been previously treated with sorafenib. This indication is … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Roche Alecensa gets USFDA nod for ALK-positive early-stage lung cancer
20 Apr 2024 09:27 GMT
… the European Medicines Agency.
Lung cancer is one of the leading … non-small cell lung cancer (NSCLC) and small-cell lung cancer. NSCLC is … despite adjuvant chemotherapy. Treating lung cancer early, before it has … Atezolizumab, Lenvatinib, and Sorafenib Study
-
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
07 Feb 2024 12:27 GMT
… cancers to date, including lung cancer, bladder cancer, esophageal … response (MPR).
About Lung Cancer
Lung cancer is the leading cause … previously treated with sorafenib. This indication is … lung cancer; Checkmate 816-neoadjuvant non-small cell lung cancer, …
-
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
11 Dec 2023 11:56 GMT
… -small cell lung cancer.”
“Addressing lung cancer reflects the … rank=1.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … previously treated with sorafenib. This indication is …
-
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
07 Dec 2023 12:21 GMT
… lung cancer.”
Merck has an extensive clinical development program in lung cancer … toxicity.
About lung cancer
Lung cancer is the … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … treated with sorafenib. This indication …
About
© 1995-2024